Iterum Therapeutics (NASDAQ:ITRM) Stock Rating Reaffirmed by HC Wainwright

Iterum Therapeutics (NASDAQ:ITRM)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They currently have a $6.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 383.87% from the company’s previous close.

Iterum Therapeutics Stock Up 7.8 %

Shares of NASDAQ ITRM opened at $1.24 on Friday. The company has a debt-to-equity ratio of 3.63, a current ratio of 1.07 and a quick ratio of 1.07. Iterum Therapeutics has a 1 year low of $0.62 and a 1 year high of $2.50. The stock has a market capitalization of $20.53 million, a P/E ratio of -0.47 and a beta of 2.29. The company has a 50-day moving average price of $1.42 and a 200-day moving average price of $1.57.

Iterum Therapeutics (NASDAQ:ITRM) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. On average, equities research analysts forecast that Iterum Therapeutics will post -1.76 EPS for the current fiscal year.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.